Timothy Schmidt, MD, University of Wisconsin

Although cytogenetic abnormalities have helped to characterize prognosis and identify patients who are at high risk of early progression, risk stratification has little effect on management decisions for most patients with multiple myeloma.

A. Timothy Schmidt, MD, discusses data from the subgroup analysis of the IKEMA study of isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma and high-risk cytogenetics that was presented at the American Society of Clinical (ASCO) 2021 Annual Meeting.